Big Pharma Challenges FDA's New Off-Label Rule

Law360, New York (February 9, 2017, 4:27 PM EST) -- Big Pharma is calling on the U.S. Food and Drug Administration to overhaul a newly finalized regulation giving the agency wide latitude to police off-label promotion, saying it contains abrupt and unconstitutional policy changes, according to a petition released Thursday.

The citizen petition was filed on Wednesday by Pharmaceutical Research and Manufacturers of America, the Biotechnology Innovation Organization and a drugmaker coalition called the Medical Information Working Group. The three organizations collectively represent virtually all major drugmakers, and their petition challenged a Jan. 9 final rule that outlined how the FDA assesses the "intended use" of prescription drugs and medical devices....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!